Is COMPASS Pathways plc (CMPS) a Buy, Sell, or Hold?
NASDAQ : CMPS
COMPASS Pathways plc
$13.55 USD
-$0.03 (-0.22%)
- Volume
- 3.42M
- Average Volume
- 4.39M
- Market Capitalization
- $1.83B
- P/E Ratio
- -2.90
- Dividend Yield
- 0.00%
- Price Target
- $19.00
- Year High
- $15.40
- Year Low
- $3.97
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.30
Company Overview
NASDAQ
Kabir Kumar Nath
Biotechnology
Healthcare
CMPS
156
GB
USD
Liquidity Metrics
0.65
1.30
1.30
1.18
0.00
Sales & Valuation
-$
0.00
21.65
-8.74
-1.55
Profitability
-$3.08
-$287.86M
0.00%
0.00%
-398.21%
-78.12%
P/E Metrics
-2.90
0.04
0.04
Analyst Price Target & Rating
$19.00
$25.00
$13.00
1/5
14 Analysts
-28.68%
Financial Health Scores
-2.42
1/9
$108.39M
$504.56M
$420.03M
-$391.7M
Key Metrics (TTM)
$1.45B
0.00
-3.71
1.30
-398.21%
-129.74%
-21.50%
-8.79%
0 days
Company Executives
| Name | Title |
|---|---|
| Guy Goodwin | Chief Medical Officer |
| Michael Gold | Chief Research & Development Officer |
| Steve Levine | Chief Patient Officer |
| Susan C. Stansfield | Advisor |
| Benjamin Harber | Company Secretary |
| Kabir Nath | Chief Executive Officer & Director |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Teri Loxam | Chief Financial Officer |
| Lars Christian Wilde | Senior Advisor |
| Lori Englebert | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About COMPASS Pathways plc (NASDAQ:CMPS) Stock
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020. ...
2026-08-06 06:30:00
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-trauma.
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 16:30:00
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of emp.
COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript
2026-08-05 15:30:09
COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcript
Compass Pathways Q2 Earnings Call Highlights
2026-08-05 09:04:44
Compass Pathways NASDAQ: CMPS said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials.
2026-08-05 06:30:00
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights. “The first half of 2026 marked a defining period for Compass as we continued to build momentum across clinical, regulatory and commercial fronts in preparation for the potential approval and launch of COMP360,” said Kabir.
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
2026-07-29 06:30:00
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://eve.
2026-07-29 05:00:00
One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares.
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum
2026-07-28 17:29:06
CMPS leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission, giving COMP360 a valuable head start in treatment-resistant depression. The core case rests on vast unmet need in depression, while encouraging PTSD data and other possible uses provide meaningful long-term upside beyond the first indication. Lilly's move for Atai validates the field and raises the competitive bar, but CMPS retains its clinical lead and cash runway; a 2% pro-forma position keeps risk proportionate.
Frequently Asked Questions
-
What is the current COMPASS Pathways plc (CMPS) stock price?
-
COMPASS Pathways plc(NASDAQ:CMPS) stock price is $13.55 in the last trading session. During the trading session, CMPS stock reached the peak price of $15.4 while $3.97 was the lowest point it dropped to. The percentage change in CMPS stock occurred in the recent session was --0.22% while the dollar amount for the price change in CMPS stock was -$0.03.
-
CMPS's industry and sector of operation?
-
The NASDAQ listed CMPS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CMPS?
-
Guy Goodwin | Chief Medical Officer
Michael Gold | Chief Research & Development Officer
Steve Levine | Chief Patient Officer
Susan C. Stansfield | Advisor
Benjamin Harber | Company Secretary -
How many employees does CMPS have?
-
Number of CMPS employees currently stands at 156. CMPS operates from 33 Broadwick Street, London, CH W1F 0DQ, GB.
-
Link for CMPS official website?
-
Official Website of CMPS is: https://compasspathways.com
-
How do I contact CMPS?
-
CMPS could be contacted at phone #44 64 6905 3974 and can also be accessed through its website. CMPS operates from 33 Broadwick Street, London, CH W1F 0DQ, GB.
-
How many shares of CMPS are traded daily?
-
The average number of CMPS shares traded daily for last 3 months was 4.39M.
-
What is the market cap of CMPS currently?
-
The market value of CMPS currently stands at $1.83B with its latest stock price at $13.55